Literature DB >> 23271276

Dexamethasone regulates differential expression of carboxylesterase 1 and carboxylesterase 2 through activation of nuclear receptors.

Chengliang Zhang1, Ping Gao1, Weifeng Yin2, Yanjiao Xu1, Daochun Xiang1, Dong Liu3.   

Abstract

Carboxylesterases (CESs) play important roles in the metabolism of endogenous and foreign compounds in physiological and pharmacological responses. The aim of this study was to investigate the effect of dexamethasone at different doses on the expression of CES1 and CES2. Imidapril and irinotecan hydrochloride (CPT-11) were used as special substrates for CES1 and CES2, respectively. Rat hepatocytes were cultured and treated with different concentrations of dexamethasone. The hydrolytic activity of CES1 and CES2 was tested by incubation experiment and their expression was quantitated by real-time PCR. A pharmacokinetic study was conducted in SD rats to further evaluate the effect of dexamethasone on CESs activity in vivo. Western blotting was performed to investigate the regulatory mechanism related to pregnane X receptor (PXR) and glucocorticoid receptor (GR). The results showed that exposure of cultured rat hepatocytes to nanomolar dexamethasone inhibited the imidapril hydrolase activity, which was slightly elevated by micromolar dexamethasone. For CES2, CPT-11 hydrolase activity was induced only when dexamethasone reached micromolar levels. The real-time PCR demonstrated that CES1 mRNA was markedly decreased by nanomolar dexamethasone and increased by micromolar dexamethasone, whereas CES2 mRNA was significantly increased by micromolar dexamethasone. The results of a complementary animal study showed that the concurrent administration of dexamethasone significantly increased the plasma concentration of the metabolite of imidapril while the ratio of CPT-11 to its metabolite SN-38 was significantly decreased. PXR protein was gradually increased by serial concentrations of dexamethasone. However, only nanomolar dexamethasone elevated the level of GR protein. The different concentrations of dexamethasone required suggested that suppression of CES1 may be mediated by GR whereas the induction of CES2 may result from the role of PXR. It was concluded that dexamethasone at different concentrations can differentially regulate CES1 and CES2.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23271276     DOI: 10.1007/s11596-012-1037-z

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  30 in total

1.  Current progress on esterases: from molecular structure to function.

Authors:  Tetsuo Satoh; Palmer Taylor; William F Bosron; Sonal P Sanghani; Masakiyo Hosokawa; Bert N La Du
Journal:  Drug Metab Dispos       Date:  2002-05       Impact factor: 3.922

2.  A single nucleotide polymorphism in the carboxylesterase gene is associated with the responsiveness to imidapril medication and the promoter activity.

Authors:  Eiichi Geshi; Tomomi Kimura; Mika Yoshimura; Hiroshi Suzuki; Shinji Koba; Tetsuo Sakai; Tsukasa Saito; Atsuro Koga; Masaaki Muramatsu; Takashi Katagiri
Journal:  Hypertens Res       Date:  2005-09       Impact factor: 3.872

3.  Gene expression profiling in the liver of CD-1 mice to characterize the hepatotoxicity of triazole fungicides.

Authors:  Amber K Goetz; Wenjun Bao; Hongzu Ren; Judith E Schmid; Douglas B Tully; Carmen Wood; John C Rockett; Michael G Narotsky; Guobin Sun; Guy R Lambert; Sheau-Fung Thai; Douglas C Wolf; Stephen Nesnow; David J Dix
Journal:  Toxicol Appl Pharmacol       Date:  2006-05-26       Impact factor: 4.219

4.  Dexamethasone differentially regulates expression of carboxylesterase genes in humans and rats.

Authors:  W Zhu; L Song; H Zhang; L Matoney; E LeCluyse; B Yan
Journal:  Drug Metab Dispos       Date:  2000-02       Impact factor: 3.922

5.  Hydrolysis of irinotecan and its oxidative metabolites, 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino] carbonyloxycamptothecin and 7-ethyl-10-[4-(1-piperidino)-1-amino]-carbonyloxycamptothecin, by human carboxylesterases CES1A1, CES2, and a newly expressed carboxylesterase isoenzyme, CES3.

Authors:  Sonal P Sanghani; Sara K Quinney; Tyler B Fredenburg; Wilhelmina I Davis; Daryl J Murry; William F Bosron
Journal:  Drug Metab Dispos       Date:  2004-05       Impact factor: 3.922

6.  Concomitant exposure of ovarian cancer cells to docetaxel, CPT-11 or SN-38 and adenovirus-mediated p53 gene therapy.

Authors:  Susanna Miettinen; Timo Ylikomi
Journal:  Anticancer Drugs       Date:  2009-08       Impact factor: 2.248

7.  Intestinal first-pass metabolism via carboxylesterase in rat jejunum and ileum.

Authors:  Kenji Masaki; Mitsuru Hashimoto; Teruko Imai
Journal:  Drug Metab Dispos       Date:  2007-03-28       Impact factor: 3.922

8.  Dexamethasone suppresses the expression of multiple rat carboxylesterases through transcriptional repression: evidence for an involvement of the glucocorticoid receptor.

Authors:  Deshi Shi; Jian Yang; Dongfang Yang; Bingfang Yan
Journal:  Toxicology       Date:  2008-09-30       Impact factor: 4.221

9.  Differential responses of rat hepatic microsomal carboxylesterase isozymes to glucocorticoids and pregnenolone 16 alpha-carbonitrile.

Authors:  M Hosokawa; K Hattori; T Satoh
Journal:  Biochem Pharmacol       Date:  1993-06-09       Impact factor: 5.858

10.  Kinetics and mechanism of inhibition of serine esterases by fluorinated aminophosphonates.

Authors:  G F Makhaeva; A Y Aksinenko; V B Sokolov; I I Baskin; V A Palyulin; N S Zefirov; N D Hein; J W Kampf; S J Wijeyesakere; R J Richardson
Journal:  Chem Biol Interact       Date:  2009-12-23       Impact factor: 5.192

View more
  2 in total

Review 1.  Regulations of Xenobiotics and Endobiotics on Carboxylesterases: A Comprehensive Review.

Authors:  Yanjiao Xu; Chengliang Zhang; Wenxi He; Dong Liu
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2016-08       Impact factor: 2.441

2.  In vitro evaluation of the inhibitory potential of pharmaceutical excipients on human carboxylesterase 1A and 2.

Authors:  Chengliang Zhang; Yanjiao Xu; Qiaoni Zhong; Xiping Li; Ping Gao; Chengyang Feng; Qian Chu; Yuan Chen; Dong Liu
Journal:  PLoS One       Date:  2014-04-03       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.